Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This is a single arm study to evaluate the efficacy, safety and tolerability of zanubrutinib
(BGB-3111) in participants with relapsed/refractory marginal zone lymphoma (R/R MZL).